We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Bristol-Myers' Opdivo Label Expansion Under U.S., EU Review
Read MoreHide Full Article
Bristol-Myers Squibb Company (BMY - Free Report) received encouraging news with the FDA accepting and the European Medicines Agency (EMA) validating the company’s marketing applications for label expansion of its immuno-oncology drug Opdivo. The company is looking to get Opdivo approved for the treatment of patients with previously treated recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN).
The company’s supplemental biologics license application for Opdivo has been accepted for priority review by the FDA. With the FDA granting priority review status, a response should be out by Nov 11, 2016. We remind investors that Opdivo was granted Breakthrough Therapy status in the U.S. for SCCHN in Apr 2016.
The EMA has validated a type II variation application for the same patient population. The validation marks the initiation of the EMA’s centralized review process.
We are encouraged by the simultaneous acceptance of Opdivo for review in the U.S. and EU. Data from the CheckMate -141 study has demonstrated that Opdivo is the first and only PD-1 inhibitor to show an overall survival benefit in a phase III study in these patients.
Per the company’s press release, head and neck cancer is the seventh most common cancer worldwide, accounting for an estimated 400,000 to 600,000 new cases per year resulting in 223,000 to 300,000 deaths annually. SCCHN accounts for approximately 90% of all head and neck cancers and is usually associated with a particularly poor prognosis and very low survival rates.
We note that Opdivo recorded worldwide revenues of $942 million in 2015. Label expansion into additional indications would give Opdivo access to an expanded patient population and increase the commercial potential of the drug.
Meanwhile, the company is working on expanding the drug’s label further. Opdivo is being evaluated for the treatment of various tumor types, alone or in combination with other approved cancer products such as Yervoy (Bristol-Myers’ other immuno-oncology drug).
Bristol-Myers is a Zacks Rank #1 (Strong Buy) stock. Other equally ranked stocks in the health care sector include Innoviva, Inc. (INVA - Free Report) , Fibrocell Science, Inc. and Nektar Therapeutics (NKTR - Free Report) .
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Bristol-Myers' Opdivo Label Expansion Under U.S., EU Review
Bristol-Myers Squibb Company (BMY - Free Report) received encouraging news with the FDA accepting and the European Medicines Agency (EMA) validating the company’s marketing applications for label expansion of its immuno-oncology drug Opdivo. The company is looking to get Opdivo approved for the treatment of patients with previously treated recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN).
The company’s supplemental biologics license application for Opdivo has been accepted for priority review by the FDA. With the FDA granting priority review status, a response should be out by Nov 11, 2016. We remind investors that Opdivo was granted Breakthrough Therapy status in the U.S. for SCCHN in Apr 2016.
The EMA has validated a type II variation application for the same patient population. The validation marks the initiation of the EMA’s centralized review process.
BRISTOL-MYERS Price
BRISTOL-MYERS Price | BRISTOL-MYERS Quote
We are encouraged by the simultaneous acceptance of Opdivo for review in the U.S. and EU. Data from the CheckMate -141 study has demonstrated that Opdivo is the first and only PD-1 inhibitor to show an overall survival benefit in a phase III study in these patients.
Per the company’s press release, head and neck cancer is the seventh most common cancer worldwide, accounting for an estimated 400,000 to 600,000 new cases per year resulting in 223,000 to 300,000 deaths annually. SCCHN accounts for approximately 90% of all head and neck cancers and is usually associated with a particularly poor prognosis and very low survival rates.
We note that Opdivo recorded worldwide revenues of $942 million in 2015. Label expansion into additional indications would give Opdivo access to an expanded patient population and increase the commercial potential of the drug.
Meanwhile, the company is working on expanding the drug’s label further. Opdivo is being evaluated for the treatment of various tumor types, alone or in combination with other approved cancer products such as Yervoy (Bristol-Myers’ other immuno-oncology drug).
Bristol-Myers is a Zacks Rank #1 (Strong Buy) stock. Other equally ranked stocks in the health care sector include Innoviva, Inc. (INVA - Free Report) , Fibrocell Science, Inc. and Nektar Therapeutics (NKTR - Free Report) .
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>